Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer

Histopathology

Volumn 66, Issue 4, 2015, Pages 491-499

  Guo, Tiantian ^a   Yu, Yingnan ^a   Yip, George Wai Cheong ^a   Baeg, Gyeong Hun ^a   Thike, Aye Aye ^b   Lim, Tony Kiat Hon ^b   Tan, Puay Hoon ^b   Matsumoto, Ken ^c   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Cell invasion; Cell migration; Immunohistochemistry; Lauren classification; Lymph node spread; YB 1

Indexed keywords

SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL INVASION; CELL MIGRATION; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE MICROARRAY; GENETICS; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1; YOUNG ADULT;

EID: 84922797286     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12570     Document Type: Article

References (37)

1. Thiel A, Ristimäki A. Gastric cancer: basic aspects. Helicobacter 2012; 17(Suppl. 1); 26-29.
2. Ajani JA, Bentrem DJ, Besh S et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 2013; 11; 531-546.
3. Wayman J, Forman D, Griffin SM. Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes Control 2001; 12; 943-949.
4. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin. Microbiol. Rev. 2010; 23; 713-739.
5. Weeks DL, Eskandari S, Scott DR, Sachs G. A H+ -gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science 2000; 287; 482-485.
6. Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J. Gastroenterol. 2014; 20; 3905-3915.
7. Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs 2011; 71; 1367-1384.
8. Ting JP, Painter A, Zeleznik-Le NJ et al. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J. Exp. Med. 1994; 179; 1605-1611.
9. Stenina OI, Poptic EJ, DiCorleto PE. Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells. J. Clin. Invest. 2000; 106; 579-587.
10. Yu YN, Yip GW, Tan PH et al. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int. J. Oncol. 2010; 37; 483-492.
11. Giménez-Bonafé P, Fedoruk MN, Whitmore TG et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59; 337-349.
12. Jürchott K, Kuban RJ, Krech T et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010; 6; e1001231.
13. Lasham A, Moloney S, Hale T et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J. Biol. Chem. 2003; 278; 35516-35523.
14. Lasham A, Samuel W, Cao H et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J. Natl Cancer Inst. 2012; 104; 133-146.
15. Chatterjee M, Rancso C, Stühmer T et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008; 111; 3714-3722.
16. Guo TT, Yu YN, Yip GW, Matsumoto K, Bay BH. Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro. Anat. Rec. (Hoboken) 2013; 296; 891-898.
17. Wu Y, Yamada S, Izumi H et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J. Surg. Oncol. 2012; 105; 724-730.
18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta. Pathol. Microbiol. Scand. 1965; 64; 31-49.
19. Tay WL, Yip GW, Tan PH et al. Y-box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod. Pathol. 2009; 22; 282-290.
20. van Rees BP, Sivula A, Thorén S et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int. J. Cancer 2003; 107; 551-556.
21. Lwin ZM, Guo C, Salim A et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod. Pathol. 2010; 23; 1559-1566.
22. Kabashima A, Yao T, Suqimachi K, Tsuneyoshi M. Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum. Pathol. 2002; 33; 80-86.
23. Cuello C, López J, Correa P, Murray J, Zarama G, Gordillo G. Histopathology of gastric dysplasias: correlations with gastric juice chemistry. Am. J. Surg. Pathol. 1979; 3; 491-500.
24. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 2005; 241; 27-39.
25. Kim SW, Kim HC, Yang DM. Perforated tumours in the gastrointestinal tract: CT findings and clinical implications. Br. J. Radiol. 2012; 85; 1307-1313.
26. Finkbeiner MR, Astanehe A, To K et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28; 1421-1431.
27. Basaki Y, Hosoi F, Oda Y et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007; 26; 2736-2746.
28. Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol. Rep. 2009; 21; 875-880.
29. Kitadai Y, Haruma K, Sumii K et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am. J. Pathol. 1998; 152; 93-100.
30. Nagashima N, Nakayama Y, Inoue Y et al. Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancer. Anticancer Res. 2008; 28; 1277-1283.
31. Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005; 16; 273-278.
32. Lee J, Seo JW, Jun HJ et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep. 2011; 25; 1517-1524.
33. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85; 1894-1902.
34. Ha SY, Lee J, Kang SY et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod. Pathol. 2013; 26; 1632-1641.
35. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001; 4; 113-121.
36. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int. Rev. Cytol. 2001; 204; 49-95.
37. Jung JH, Kim HJ, Yeom J et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J. Gastroenterol. 2012; 47; 37-48.